Literature DB >> 15800406

Feeding strategies and necrotizing enterocolitis.

Carol Lynn Berseth1.   

Abstract

PURPOSE OF REVIEW: To update clinical trials concerning feeding strategies or feeding interventions to prevent necrotizing enterocolitis (NEC). RECENT
FINDINGS: The overall incidence of NEC remains unchanged. Several studies have shown that it is safe to use small feeding volumes early in life even in selected circumstances, such as feeding during the use of indomethacin to treat symptomatic patent ductus arteriosus. Although descriptive case reports have linked some feeding interventions such as thickened feedings to NEC, there is no evidence to establish a causal relation. Interestingly, one report showed that neither the presence of-nor characteristics of-gastric residuals was helpful to identify those infants who subsequently develop NEC. Numerous studies in animals show that vascular and host defense responses are not adequate in the immature gut. A few small clinical trials showed that various feeding strategies may alter these responses in preterm infants. However, larger clinical trials around these issues await further characterization of the mechanisms that regulate these two aspects of gastrointestinal function with respect to feeding.
SUMMARY: Studies continue to demonstrate how fragile the immature gut is, but further work directed to understanding the mechanisms that regulate gastrointestinal responses to feeding is needed to design meaningful interventions for large prospective trials.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15800406     DOI: 10.1097/01.mop.0000150566.50580.26

Source DB:  PubMed          Journal:  Curr Opin Pediatr        ISSN: 1040-8703            Impact factor:   2.856


  8 in total

1.  Toll-like receptor 4 is protective against neonatal murine ischemia-reperfusion intestinal injury.

Authors:  Philip M Tatum; Carroll M Harmon; Robin G Lorenz; Reed A Dimmitt
Journal:  J Pediatr Surg       Date:  2010-06       Impact factor: 2.545

Review 2.  Multi-modal approach to prophylaxis of necrotizing enterocolitis: clinical report and review of literature.

Authors:  G Schmolzer; B Urlesberger; Michaela Haim; J Kutschera; G Pichler; E Ritschl; B Resch; F Reiterer; W Müller
Journal:  Pediatr Surg Int       Date:  2006-06-15       Impact factor: 1.827

3.  Supplementing monosodium glutamate to partial enteral nutrition slows gastric emptying in preterm pigs(1-3).

Authors:  Caroline Bauchart-Thevret; Barbara Stoll; Nancy M Benight; Oluyinka Olutoye; David Lazar; Douglas G Burrin
Journal:  J Nutr       Date:  2013-02-27       Impact factor: 4.798

4.  Low Abdominal NIRS Values and Elevated Plasma Intestinal Fatty Acid-Binding Protein in a Premature Piglet Model of Necrotizing Enterocolitis.

Authors:  Irving J Zamora; Barbara Stoll; Cecilia G Ethun; Fariha Sheikh; Ling Yu; Douglas G Burrin; Mary L Brandt; Oluyinka O Olutoye
Journal:  PLoS One       Date:  2015-06-10       Impact factor: 3.240

5.  Evidence vs experience in neonatal practices in necrotizing enterocolitis.

Authors:  C J Hunter; B Podd; H R Ford; V Camerini
Journal:  J Perinatol       Date:  2008-05       Impact factor: 2.521

6.  Necrotizing enterocolitis in infants with ductal-dependent congenital heart disease.

Authors:  Kristian C Becker; Christoph P Hornik; C Michael Cotten; Reese H Clark; Kevin D Hill; P Brian Smith; Robert W Lenfestey
Journal:  Am J Perinatol       Date:  2014-12-08       Impact factor: 3.079

7.  Risk Factors for Necrotizing Enterocolitis in Infants With Patent Arterial Duct. A Retrospective Matched Paired Analysis.

Authors:  Stephanie Haefeli; Marcin Kordasz; Catherine Tsai; Eva-Maria Hau; Peter Klimek; Dietmar Cholewa; Mladen Pavlovic; Steffen Berger; Ulf Kessler
Journal:  Front Pediatr       Date:  2020-04-28       Impact factor: 3.418

8.  High-dose oral erythromycin decreased the incidence of parenteral nutrition-associated cholestasis in preterm infants.

Authors:  Pak C Ng; Cheuk H Lee; Samuel P S Wong; Hugh S Lam; Flora Y B Liu; King W So; Cheuk Y Lee; Tai F Fok
Journal:  Gastroenterology       Date:  2007-03-24       Impact factor: 22.682

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.